Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients

NCT06443905 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 21600

Last updated 2024-06-05

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy, safety and cost-effectiveness of Xueshuantong (lyophilized) for the prevention of venous thromboembolism (VTE) in patients at risk of bleeding.

Conditions

  • Venous Thromboembolism (VTE)
  • Thromboembolism

Sponsors & Collaborators

  • Guangxi Wuzhou Pharmaceutical (GROUP) Co., Ltd.

    collaborator UNKNOWN
  • China-Japan Friendship Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-06-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06443905 on ClinicalTrials.gov